Botanix Pharmaceuticals Ltd
BOT
Company Profile
Business description
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.
Contact
41 - 47 Colin Street
Suite 3
West PerthWA6005
AUST: +61 865552945
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
1
Stocks News & Analysis
stocks
3 Warren Buffett stocks to avoid today
These are the most overvalued stocks in Berkshire Hathaway’s portfolio.
stocks
Should you invest in small caps?
With small capitalisation stocks gaining momentum, there are important considerations to determine whether they are right for your portfolio.
stocks
Strong second half anticipated for ASX mining play
A more focused business model should benefit the company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,066.40 | 4.90 | 0.05% |
| CAC 40 | 7,795.42 | 32.03 | -0.41% |
| DAX 40 | 23,534.83 | 131.98 | -0.56% |
| Dow JONES (US) | 45,947.32 | 173.96 | -0.38% |
| FTSE 100 | 9,213.98 | 36.45 | -0.39% |
| HKSE | 26,274.99 | 209.69 | -0.79% |
| NASDAQ | 22,384.70 | 113.16 | -0.50% |
| Nikkei 225 | 45,522.80 | 232.13 | -0.51% |
| NZX 50 Index | 13,113.26 | 40.53 | -0.31% |
| S&P 500 | 6,604.72 | 33.25 | -0.50% |
| S&P/ASX 200 | 8,776.70 | 2.20 | 0.03% |
| SSE Composite Index | 3,846.33 | 6.97 | -0.18% |